• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Articles by Marie Powers

On the cusp of solving delivery challenges, is the 'golden age' ahead for RNAi?

March 27, 2015
By Marie Powers

Arrowhead Research Corp.'s pick-up of the entire RNAi portfolio of Novartis AG earlier this month, including rights to a host of intellectual property (IP) and assets – among them, an existing license agreement with RNAi powerhouse Alnylam Pharmaceuticals Inc. – all but closed the door to big pharma's decade-long experiment in RNAi-based drugs.


Read More

NASH flash: Emricasan data boost Conatus; Genfit falls on fuzzy findings

March 27, 2015
By Marie Powers
In January, investors in Conatus Pharmaceuticals Inc. showed their displeasure with early stage pharmacokinetic and pharmacodynamic findings on the use of emricasan in patients with impaired liver function by sending the company's shares (NASDAQ:CNAT) into a 40 percent freefall.
Read More

La Jolla Pharma takes lead drug, LJPC-501, into first phase III

March 25, 2015
By Marie Powers
La Jolla Pharmaceutical Co. (LJP) moved ever so cautiously into its first phase III trial in more than a decade, advancing lead compound LJPC-501 (angiotensin II) into ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 to treat catecholamine-resistant hypotension (CRH).
Read More

After 'quiet' work on tanezumab, Pfizer, Lilly look to resume phase III

March 24, 2015
By Marie Powers
Pfizer Inc. and Eli Lilly and Co. are preparing to resume the phase III program for their partnered pain candidate, tanezumab, that has been in limbo since 2010, when the FDA raised concerns about a small number of osteoarthritis (OA) patients in the tanezumab program whose OA worsened, necessitating joint replacement.
Read More

'Most Promising Drugs of 2015' span gamut of companies, indications

March 23, 2015
By Marie Powers
An annual forecast of drugs expected to debut in the coming year and eventually reach blockbuster status suggests the biopharma industry is not only alive and well but also not solely reliant on compounds that target the narrower indications implicit in precision medicine efforts.
Read More

Aducanumab, AD still golden for Biogen Idec in updated phase I findings

March 23, 2015
By Marie Powers
It's increasingly difficult to generate a big move in shares of a big biotech, but Alzheimer's disease (AD) did the trick again for Biogen Idec Inc., which continued to report upbeat findings for aducanumab (BIIB037) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France.
Read More

CAR T mystique lassos City of Hope: Coronado to advance technology at Mustang

March 20, 2015
By Marie Powers
If anyone still doubted the power of chimeric antigen receptor T-cell (CAR T) technology to propel pipelines and stock prices, they needed look no further than the cross-country deal between Coronado Biosciences Inc. and the City of Hope to advance a portfolio of assets in newly created Mustang Therapeutics Inc.
Read More

Scioderm initiates phase III trial of Zorblisa, targets sea change to treat rare disorder

March 19, 2015
By Marie Powers
Just three years out of the gate, privately held Scioderm Inc. is starting a phase III registration trial of lead compound Zorblisa (SD-101), its topical therapy to treat blisters and lesions resulting from the rare genetic connective tissue disorder epidermolysis bullosa (EB).
Read More

Beyond seasons and borders, Beyondspring seeks cross-cultural cancer answer

March 18, 2015
By Marie Powers
Beyondspring Pharmaceuticals Inc. literally sprang to life in June 2013 with a phase II cancer compound already in hand. In the second quarter, the company's lead compound, plinabulin, is set to enter a pivotal phase III trial in patients with non-small-cell lung cancer (NSCLC), a notoriously obstinate indication.
Read More

Beyond seasons and borders, Beyondspring seeks cross-cultural cancer answer

March 18, 2015
By Marie Powers
Beyondspring Pharmaceuticals Inc. literally sprang to life in June 2013 with a phase II cancer compound already in hand.
Read More
Previous 1 2 … 85 86 87 88 89 90 91 92 93 … 168 169 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 23, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • Illustration of liver with DNA double helixes

    ASGCT 2025: Gene and cell therapies transform metabolic diseases

    BioWorld Science
    Metabolic disorders such as argininosuccinic and glutaric aciduria, methylmalonic acidemia, homocystinuria or primary hyperoxaluria require specific diets to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe